A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative.

CRD summary This review assessed routine antenatal anti-D prophylaxis (AADP) for pregnant women who are Rhesus-negative. Routine AADP reduced the number of Rhesus-negative women who were sensitised during pregnancy. Some instances of sensitisation could still occur before or despite administration of AADP. The conclusions appear supported by the evidence presented, though the variable quality of included studies should be noted.

[1]  I. Mackenzie,et al.  Routine antenatal Rhesus D immunoglobulin prophylaxis: the results of a prospective 10 year study , 1999, British journal of obstetrics and gynaecology.

[2]  R. Beard,et al.  Management of bleeding in early pregnancy in accident and emergency departments , 1994, BMJ.

[3]  S. Vick,et al.  Cost-effectiveness of antenatal anti-D prophylaxis. , 1996, Health economics.

[4]  R. Brand,et al.  MORBIDITY OF VERY LOW BIRTHWEIGHT INFANTS AT CORRECTED AGE OF TWO YEARS IN A GEOGRAPHICALLY DEFINED POPULATION Report from Project On Preterm and Small for Gestational Age Infants in the Netherlands , 1989, The Lancet.

[5]  T. Baskett,et al.  Prevention of Rh(D) alloimmunization: a cost-benefit analysis. , 1990, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[6]  M. Conaway,et al.  Health status of children with moderate to severe cerebral palsy , 2001, Developmental medicine and child neurology.

[7]  A Laupacis,et al.  Assessing the quality of randomized trials: reliability of the Jadad scale. , 1999, Controlled clinical trials.

[8]  D. Krüger,et al.  Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin , 1995, The Lancet.

[9]  L. Doyle,et al.  The cost of improving the outcome for infants of birthweight 500‐999 g in Victoria: THE VICTORIAN INFANT COLLABORATIVE STUDY GROUP , 1993, Journal of paediatrics and child health.

[10]  K. Moise,et al.  Long-term neurodevelopmental outcome after intrauterine transfusion for the treatment of fetal hemolytic disease. , 1998, American journal of obstetrics and gynecology.

[11]  G. Torrance,et al.  Cost-effectiveness of antepartum prevention of Rh immunization. , 1984, Clinics in perinatology.

[12]  M. Jensen,et al.  Pain in persons with cerebral palsy. , 1999, Archives of physical medicine and rehabilitation.

[13]  H R Rubin,et al.  Cost-utility analysis of the cochlear implant in children. , 2000, JAMA.

[14]  J. Marks,et al.  Cost implications of routine antenatal administration of Rh immune globulin. , 1984, American journal of obstetrics and gynecology.

[15]  J M Bowman,et al.  Failures of intravenous Rh immune globulin prophylaxis: an analysis of the reasons for such failures. , 1987, Transfusion medicine reviews.

[16]  P. Tappenden,et al.  A review of the clinical effectiveness of routine antenatal anti‐D prophylaxis for rhesus‐negative women who are pregnant , 2004, BJOG : an international journal of obstetrics and gynaecology.

[17]  B. McClure,et al.  Preventing RhD haemolytic disease of the newborn. Services should be centralised for pregnancies affected by RhD haemolytic disease. , 1998, BMJ.

[18]  L. Leader,et al.  Donor insemination: effects on parents , 1995, The Medical journal of Australia.

[19]  L. Tovey,et al.  THE YORKSHIRE ANTENATAL ANTI-D IMMUNOGLOBULIN TRIAL IN PRIMIGRAVIDAE , 1983, The Lancet.

[20]  P. Simmonds,et al.  Hepatitis C infection from anti-D immunoglobulin , 1995, The Lancet.

[21]  B Chown,et al.  Rh isoimmunization during pregnancy: antenatal prophylaxis. , 1978, Canadian Medical Association journal.

[22]  R. Brand,et al.  Outcome for children treated with fetal intravascular transfusions because of severe blood group antagonism. , 1997, The Journal of pediatrics.

[23]  J. Thornton,et al.  Efficacy and long term effects of antenatal prophylaxis with anti-D immunoglobulin. , 1989, BMJ.

[24]  J M Bowman,et al.  Antenatal prophylaxis of Rh isoimmunization: 28-weeks'-gestation service program. , 1978, Canadian Medical Association journal.

[25]  E. Tabor.  The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1 , 1999, Transfusion.

[26]  Jesse A Berlin,et al.  Does blinding of readers affect the results of meta-analyses? , 1997, The Lancet.

[27]  H J Stam,et al.  Functional level of young adults with cerebral palsy , 2001, Clinical rehabilitation.

[28]  D Lee,et al.  Multicentre trial of antepartum low‐dose anti‐D immunoglobulin , 1995, Transfusion medicine.

[29]  J. Ironside,et al.  Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues , 2001, The Lancet.

[30]  Birgitta Trolle,et al.  Prenatal Rh‐Immune Prophylaxis With 300 μg Immune Globulin Anti‐D In The 28th Week Of Pregnancy , 1989 .

[31]  S. Urbaniak,et al.  RhD haemolytic disease of the fetus and the newborn. , 2000, Blood reviews.

[32]  F. Klumper,et al.  The severity of immune fetal hydrops is predictive of fetal outcome after intrauterine treatment. , 2001, American journal of obstetrics and gynecology.

[33]  M. Turner,et al.  New-variant Creutzfeldt-Jakob disease: the risk of transmission by blood transfusion. , 1998, Blood reviews.

[34]  S Mayne,et al.  Rate of RhD sensitisation before and after implementation of a community based antenatal prophylaxis programme , 1997, BMJ.

[35]  B. Trolle.  Prenatal Rh-immune prophylaxis with 300 micrograms immune globulin anti-D in the 28th week of pregnancy. , 1989, Acta obstetricia et gynecologica Scandinavica.